Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Posterior chamber phakic intraocular lens implantation in keratoconic eyes: long-term changes in visual acuity

Search Title by author or title

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 17:57

Venue: Hall C4

First Author: : D.Badoza ARGENTINA

Co Author(s): :    E. Benitez Saldivar   S. Ambrosetto   M. Cosentino              

Abstract Details


To evaluate long-term evolution of visual acuity (VA) after posterior-chamber phakic intraocular lens implantation in keratoconic eyes


Instituto de la Visión, Buenos Aires, Argentina


We retrospectively studied 18 eyes of 11 patients with keratoconus in which Visian Toric ICL was implanted. Age was 37.8 ±12.2 years-old. We analyzed evolution of refraction and VA at 1 month, 1 year, 2 years, and 3 years.


Preoperative sphere, was -7.1±5.7D and cylinder was -4.2±1.5D; Uncorrected Visual Acuity (UCVA) was less than 20/70 in 100% of the cases, whereas Best Corrected Visual Acuity (BCVA) was 20/40 or better in 6 eyes (33.3%). Follow-up was 26.3±10.3 months. At postoperative first month, sphere and cylinder were 0.00±0.91D and -0.8±1.5D, respectively. No statistically significant differences in following examinations were found. UCVA was 20/40 or better in 55.5% at month 1, in 72.2% at year 2, and in 66.6% at year 3. No case had lost lines of BCVA, and 2.0±1.4 lines of VA were gained at month 1, comparing with 2.6±1.6 at year 3. Efficacy and Safety Indexes were 1.45 and 1.69, respectively


Implantation of posterior-chamber phakic intraocular lens in eyes with keratoconus is an effective and safe procedure. Additionally, in some cases, improvement of both UCVA and BCVA continues on long term follow-up.

Financial Disclosure:


Back to previous